UCL Business: Two new funds to support research commercialisation
29 September 2016
The launch this year of the
Both funds are supported by UCL Business, UCL's technology commercialisation company whose aim is to help researchers develop their innovations into opportunities that are attractive to business and investors.
The £40 million Apollo Therapeutics Fund is dedicated to life sciences. The £50 million UCL Technology Fund is open to all disciplines in the university, with up to £100k available for proof of concept and up to £2.5m for further funding.
The UCL Technology Fund - the first investment fund ever launched by UCL - aims to support innovations from academics in all areas of the university, including engineering, information communication technology and life sciences and will help academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies over the next five years. The Apollo Therapeutics Fund is a partnership between UCL, Imperial College and Cambridge University and AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and aims to accelerate the translation of university research into new medicines.
It is the first time global pharmaceutical companies and world-leading universities have created this type of fund.
The Fund will provide finance (up to £3 million) to mid-stage pre-clinical therapeutic projects emanating from UCL and the other two universities.
UCL Business is holding an event from 4pm to 6pm on 13 October in the South Cloisters to give researchers more information about the Apollo Therapeutics Fund.
For further information, visit:
http://www.ucl.ac.uk/enterprise/staff/funding#apollo (UCL password protected)